These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 26810535)

  • 1. Short-term suboptimal response criteria for predicting long-term non-response to first-line disease modifying therapies in multiple sclerosis: A systematic review and meta-analysis.
    Río J; Ruiz-Peña JL
    J Neurol Sci; 2016 Feb; 361():158-67. PubMed ID: 26810535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term impact of interferon or Glatiramer acetate in multiple sclerosis: A systematic review and meta-analysis.
    Signori A; Gallo F; Bovis F; Di Tullio N; Maietta I; Sormani MP
    Mult Scler Relat Disord; 2016 Mar; 6():57-63. PubMed ID: 27063624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pediatric-onset multiple sclerosis in Brazilian patients: Clinical features, treatment response and comparison to pediatric neuromyelitis optica spectrum disorders.
    Fragomeni MO; Bichuetti DB; Oliveira EML
    Mult Scler Relat Disord; 2018 Oct; 25():138-142. PubMed ID: 30075406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation.
    Melendez-Torres GJ; Auguste P; Armoiry X; Maheswaran H; Court R; Madan J; Kan A; Lin S; Counsell C; Patterson J; Rodrigues J; Ciccarelli O; Fraser H; Clarke A
    Health Technol Assess; 2017 Sep; 21(52):1-352. PubMed ID: 28914229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate.
    Healy BC; Glanz BI; Zurawski JD; Mazzola M; Chitnis T; Weiner HL
    J Neurol Sci; 2018 Nov; 394():127-131. PubMed ID: 30248571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
    Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The UK Risk-Sharing Scheme for interferon-beta and glatiramer acetate in multiple sclerosis. Outcome of the year-6 analysis.
    Duddy M; Palace J
    Pract Neurol; 2016 Feb; 16(1):4-6. PubMed ID: 26430247
    [No Abstract]   [Full Text] [Related]  

  • 9. Characteristics influencing therapy switch behavior after suboptimal response to first-line treatment in patients with multiple sclerosis.
    Teter B; Agashivala N; Kavak K; Chouhfeh L; Hashmonay R; Weinstock-Guttman B
    Mult Scler; 2014 Jun; 20(7):830-6. PubMed ID: 24277325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
    Roskell NS; Zimovetz EA; Rycroft CE; Eckert BJ; Tyas DA
    Curr Med Res Opin; 2012 May; 28(5):767-80. PubMed ID: 22462530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature.
    Mahurkar S; Suppiah V; O'Doherty C
    Autoimmun Rev; 2014 Feb; 13(2):178-86. PubMed ID: 24189284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early versus later treatment start in multiple sclerosis: a register-based cohort study.
    Chalmer TA; Baggesen LM; Nørgaard M; Koch-Henriksen N; Magyari M; Sorensen PS;
    Eur J Neurol; 2018 Oct; 25(10):1262-e110. PubMed ID: 29847005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis.
    Kalincik T; Jokubaitis V; Izquierdo G; Duquette P; Girard M; Grammond P; Lugaresi A; Oreja-Guevara C; Bergamaschi R; Hupperts R; Grand'Maison F; Pucci E; Van Pesch V; Boz C; Iuliano G; Fernandez-Bolanos R; Flechter S; Spitaleri D; Cristiano E; Verheul F; Lechner-Scott J; Amato MP; Cabrera-Gomez JA; Saladino ML; Slee M; Moore F; Gray O; Paine M; Barnett M; Havrdova E; Horakova D; Spelman T; Trojano M; Butzkueven H;
    Mult Scler; 2015 Aug; 21(9):1159-71. PubMed ID: 25480857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme.
    Palace J; Duddy M; Lawton M; Bregenzer T; Zhu F; Boggild M; Piske B; Robertson NP; Oger J; Tremlett H; Tilling K; Ben-Shlomo Y; Lilford R; Dobson C
    J Neurol Neurosurg Psychiatry; 2019 Mar; 90(3):251-260. PubMed ID: 30242090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease-modifying agents in the treatment of multiple sclerosis: a review of long-term outcomes.
    Katrych O; Simone TM; Azad S; Mousa SA
    CNS Neurol Disord Drug Targets; 2009 Dec; 8(6):512-9. PubMed ID: 19811446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical markers of therapeutic response to disease modifying drugs.
    Pozzilli C; Prosperini L
    Neurol Sci; 2008 Sep; 29 Suppl 2():S211-3. PubMed ID: 18690494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain atrophy as a non-response predictor to interferon-beta in relapsing-remitting multiple sclerosis.
    Rojas JI; Patrucco L; Miguez J; Besada C; Cristiano E
    Neurol Res; 2014 Jul; 36(7):615-8. PubMed ID: 24620963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple sclerosis disease-modifying therapy and pregnancy.
    Miller AE
    Mult Scler; 2016 May; 22(6):715-6. PubMed ID: 27207870
    [No Abstract]   [Full Text] [Related]  

  • 20. Short- and long-term clinical outcomes of use of beta-interferon or glatiramer acetate for people with clinically isolated syndrome: a systematic review of randomised controlled trials and network meta-analysis.
    Armoiry X; Kan A; Melendez-Torres GJ; Court R; Sutcliffe P; Auguste P; Madan J; Counsell C; Clarke A
    J Neurol; 2018 May; 265(5):999-1009. PubMed ID: 29356977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.